← 返回

嵌合抗原受体自然杀伤(CAR-NK)细胞:从临床前前景到肿瘤免疫治疗的临床现实

英文原题:Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.

查看英文原题

Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.

PubMed 2025/11/04(内容时间) Immunotherapy Q3 · IF 2.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)自然杀伤(NK)细胞疗法代表了癌症免疫治疗的一个新兴前沿。CAR-NK 细胞提供了“现货型”治疗的潜力,并具有有利的安全性特征,部分原因在于其固有的 HLA 非限制性肿瘤靶向能力以及不引起移植物抗宿主病。使用脐带血来源 CAR-NK 细胞的里程碑式临床研究以及另一项使用 iPSC 来源 CAR-NK 细胞的研究,已报告了令人瞩目的缓解率、持久缓解和极小的毒性。此外,越来越多的正在进行的临床试验正在探索创新策略,以增强持久性、克服实体瘤挑战并防止抗原逃逸。这些进展共同凸显了 CAR-NK 疗法革新癌症治疗的潜力,同时解决了当前 CAR-T 细胞方法相关的局限性。

展开英文摘要原文

Chimeric antigen receptor (CAR) natural killer (NK) cell therapy represents an emerging frontier in cancer immunotherapy. CAR-NK cells offer the potential for "off-the-shelf" treatments with a favorable safety profile, due in part to their innate capacity for HLA-unrestricted tumor targeting and an absence of graft-versus-host disease. Landmark clinical studies using cord blood - derived CAR-NK cells and another employing iPSC-derived CAR-NK cells have reported impressive response rates, durable remissions, and minimal toxicity.

Furthermore, a growing landscape of ongoing clinical trials is exploring innovative strategies to enhance persistence, overcome solid tumor challenges, and prevent antigen escape. These advances collectively underscore the potential of CAR-NK therapies to revolutionize cancer treatment while addressing limitations associated with current CAR-T cell approaches.

论文信息

作者
Cochran HC、Ghobadi KA、Ghobadi A
单位
Washington University School of Medicine, Center for Gene and Cellular Immunotherapy (CGCI), St Louis, MO, USA.United States
文献类型
综述
期刊
Immunotherapy2025 Oct
原文标识
PubMed 41186143 · DOI 10.1080/1750743X.2025.2582464